This $1.3b biotech is still run out of a spare bedroom in Melbourne
It’s been a volatile few years for Neuren, the neurological disorder treatment group which has seen shares rocket, then slump. Now it has a promising new drug.
Jon Pilcher’s spare bedroom in Melbourne’s southern suburbs is the unlikely engine room of a $1.3 billion global biotech.
The chief executive of Neuren Pharmaceuticals has overseen two capital raisings and the rapid growth of the company, which has developed the world’s first approved drug to treat Rett syndrome, a neurological disorder disrupting signalling between brain cells mainly in young girls.
Michael SmithHealth editorMichael Smith is the health editor for The Australian Financial Review. He is based in Sydney. Connect with Michael on Twitter. Email Michael at michael.smith@afr.com
